(Kezar) Shares of Kezar Life Sciences rose more than 77% on Tuesday after reporting positive topline results for its novel selective immunoproteasome inhibitor.
The company said that a Phase 2 clinical trial for zetomipzomib, the first-in-class inhibitor in patients with active lupus nephritis, showed meaningful renal response after six months. The response was produced without high-dose induction therapy.
Kezar said that patients in the trial also had reductions in extra-renal manifestations of lupus. Zetomipzomib was also well-tolerated and steroid-sparing.
The company expects to continue developing zetomipzomib for patients with lupus nephritis. It will also explore development opportunities for systemic lupus erythematosus.
KZR:NASDAQ is up +79.24% in premarket
